Assess whether to resubmit, meet, or pause the program (94ba2f)

SITUATION Clinical and Evidence Strategy work in a biologics company planning a biosimilar pathway now turns on to resubmit, meet, or because a competitor label that just got a narrower indication put biosimilar analytical similarity report in play. Clinical-development physician should say what biosimilar analytical similarity report proves.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; biosimilar analytical similarity report already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the program in force until biosimilar analytical similarity report is completed after a competitor label that just got a narrower indication for clinical-development physician. 3. Treat biosimilar analytical similarity report as To resubmit, meet, because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to resubmit, meet, or turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Check whether biosimilar analytical similarity report supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 3. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a competitor label that just got a narrower indication. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for clinical-development physician - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in biosimilar analytical similarity report that a second reviewer can re-perform